Trying to measure a symptom patients know well but medicine struggles to quantify
Cancer survivors often describe a form of fatigue that is hard to explain and even harder to measure. Treatment may be over. Scans may be clear. Yet some patients still feel profoundly drained, unable to sustain ordinary daily activity. Clinicians have long relied mostly on surveys to understand that fatigue, leaving a gap between what patients report and what medicine can objectively observe.
A pilot study highlighted by Medical Xpress points to a possible way of narrowing that gap. Researchers from Rutgers University, Johns Hopkins University, and the National Institute on Aging used a specialized MRI-based technique to look directly at how skeletal muscle cells restored energy after exertion in cancer survivors. The work does not offer a cure, and it involves only 11 participants, but it suggests that persistent fatigue may be traceable through measurable mitochondrial recovery inside muscle tissue rather than only through subjective questionnaires.
How the study worked
The researchers used phosphorus-31 magnetic resonance spectroscopy, or 31P-MRS, a National Institutes of Health-validated MRI test for mitochondrial measurement. Participants lay in a scanner with a coil positioned over the left thigh. After performing a short, vigorous knee-extension exercise designed to deplete energy stores, they remained under observation while the scanner tracked how quickly those stores rebuilt.
The logic is straightforward. Mitochondria generate the energy cells use to function. If recovery after exertion is slower, it can indicate weaker mitochondrial performance. Instead of inferring fatigue only from how a patient feels or what they can report on a form, the researchers tried to watch a key biological recovery process directly.
According to the supplied report, that kind of close look at single-cell-specific biology had not previously been used in this way for cancer survivor fatigue. Senior author Leorey Saligan emphasized the importance of examining muscle-level biology instead of depending on blood markers, which can shift constantly.
What the pilot study found
The 11 participants ranged from 34 to 70 years old and had undergone treatment for various cancers, including combinations of surgery, chemotherapy, radiation, immunotherapy, and hormone therapy. Within that small cohort, participants aged 65 and older showed about 10 percent slower muscle energy recovery than younger patients. They also had weaker grip strength, higher self-reported fatigue, and fewer daily steps.
Those findings matter because they line up biology with lived experience. Older participants were not only saying they felt more fatigued. They also showed slower restoration of cellular energy reserves and reduced physical performance on other measures. That kind of convergence can help move fatigue from a vague symptom category toward something clinicians can test, track, and perhaps eventually target more precisely.
The study does not prove that mitochondrial dysfunction is the sole cause of post-treatment fatigue, nor does it establish a universal pattern across all cancer survivors. But it does suggest that at least one measurable component of the problem may sit in the muscles themselves.
Why objective measurement matters
Fatigue is one of the most frustrating symptoms in medicine because it cuts across disease areas while resisting neat quantification. In cancer survivorship, that difficulty can become especially painful. Patients may look healthy by conventional metrics and still feel incapable of doing basic tasks. When the clinical toolkit depends heavily on self-report, it can be harder to classify severity, compare patients, monitor changes over time, or evaluate whether an intervention is working.
An imaging-based measure changes that equation, even if only incrementally at first. If clinicians can identify a biological signature associated with persistent fatigue, they gain a more concrete basis for diagnosis and follow-up. Researchers, in turn, gain a potential endpoint for testing therapies aimed at improving recovery, strength, or mitochondrial function.
That does not mean the subjective experience of fatigue becomes less important. In fact, the value of this study is partly that it respects patient experience enough to search for a mechanism behind it.
The limits are as important as the promise
Because this was a pilot study with only 11 participants, the findings should be treated as early evidence rather than settled guidance. Small samples can reveal a signal, but they can also overstate one. The participants had different cancer histories and different treatment exposures, which may affect fatigue through multiple pathways. Age itself is also a confounding factor when studying strength, activity, and mitochondrial recovery.
Even so, pilot studies serve an important role. They test whether a method is feasible, whether it can capture meaningful variation, and whether larger investigations are warranted. On those terms, this work appears to have produced a persuasive reason to continue.
The study’s design is also notable because it linked imaging to practical measures such as grip strength, self-reported fatigue, and daily step counts. That kind of multi-layered assessment may be crucial in future research. Fatigue is not a single number. It is a mix of biology, function, and perception. The most useful tools will likely connect all three.
What could come next
The longer-term value of this work lies in what it may enable. If larger studies confirm that slower mitochondrial recovery tracks with cancer-related fatigue, clinicians could eventually use similar methods to identify patients at higher risk, tailor rehabilitation strategies, or measure whether exercise, drugs, or other interventions improve muscle energetics.
That future is still hypothetical. The current study does not validate a new clinical standard. But it does move the conversation forward by shifting the question from “Is this symptom real?” to “What is the biology underlying it, and how can we measure it better?”
For cancer survivors living with exhausting symptoms after treatment, that is a meaningful change in framing. Medicine often advances first by improving measurement. Only then does treatment get sharper. This pilot study suggests that persistent fatigue, long difficult to pin down, may be entering that first stage of clearer definition.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
